Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03226158
Other study ID # PREDSEQ
Secondary ID
Status Active, not recruiting
Phase
First received
Last updated
Start date August 9, 2017
Est. completion date May 1, 2025

Study information

Verified date May 2024
Source St. Jude Children's Research Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The majority of children and adolescents diagnosed with cancer will experience one or more episodes of fever or infection during their course of therapy. The most common microbiologically documented infection is bloodstream infection (BSI), which can be associated with severe sepsis or death. Current methods of diagnosis require a significant load of live bacteria in the blood making early detection difficult. Delayed diagnosis and delayed optimal therapy of BSIs are associated with increased morbidity and mortality. This study seeks to identify whether next generation sequencing (NGS) of pathogens can identify patients with impending bloodstream infection. This would enable preemptive targeted therapy to replace antibacterial prophylaxis which often leads ot high-density broad-spectrum antibiotic exposure and contributes to subsequent development of antibiotic resistance. PRIMARY OBJECTIVE: - To estimate the sensitivity and specificity of next generation pathogen sequencing for prediction of bloodstream infection in children with cancer at high risk of infection.


Description:

Plasma samples collected but not required for clinical care (discarded samples) will be collected and stored. Results of NGS will be compared between patients who develop BSI immediately (within 72 hours) after sample collection, those who develop other infectious syndromes, and those who remain well. Clinical data describing baseline information about the patient and malignancy, antibiotic and chemotherapy exposure, microbiology testing, hematology results, and infection-related events will be collected prospectively from the electronic medical record. An initial exploratory phase will examine approximately 50 participants to determine whether the effectiveness of predicting infections. The study may then enroll up to 200 participants to collection additional data for analysis.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 160
Est. completion date May 1, 2025
Est. primary completion date March 1, 2022
Accepts healthy volunteers No
Gender All
Age group N/A to 24 Years
Eligibility Inclusion Criteria: - Under 25 years of age at time of study enrollment - Undergoing care for cancer at St. Jude - In a category of patients who are considered by the investigator to be at high risk of infection - Expected to receive care at St. Jude for at least 7 days Exclusion Criteria: - Any condition that would, in the opinion of the investigator, place the subject at an unacceptable risk of injury or render the subject unable to meet the requirements of the protocol.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
United States St. Jude Children's Research Hospital Memphis Tennessee

Sponsors (2)

Lead Sponsor Collaborator
St. Jude Children's Research Hospital Karius, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Proportion of NGS-positive results To estimate the sensitivity of next generation pathogen sequencing for prediction of BSI, the proportion of NGS-positive results in all positive BSI cultures will be given. Once (within 72 hours of enrollment)
Primary Proportion of NGS-negative results To estimate the specificity of next generation pathogen sequencing for prediction of BSI, the proportion of NGS-negative results in all negative BSI cultures will be given. Once (within 72 hours of enrollment)
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05361135 - 18-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in S. Aureus Bacteraemia N/A
Completed NCT02400268 - Antibiotic Treatment Duration (7 vs 14 Days) Comparison in Blood Stream Infection Causes by Enterobacteriaceae Phase 3
Recruiting NCT04070820 - Combination Treatment for Enterococcus Faecalis Bacteriemia Multicenter, Observational Study"
Completed NCT03147807 - BetaLACTA® Test for Early De-escalation of Empirical Carbapenems in Pulmonary, Urinary and Bloodstream Infections in ICU N/A
Completed NCT05411315 - Pragmatic Randomized Trial for Arterial Catheters in the Critical Care Environment N/A
Enrolling by invitation NCT05880069 - Clinical Outcomes in Patients With Infection by Resistant Microorganism
Terminated NCT04250168 - Piloting Clinical Bacteriology in the Ebola Virus Disease Care Response
Terminated NCT04876430 - Best Available Therapy With or Without Meropenem for Bloodstream Infections by Enterobacterales With High Level of Resistance to Carbapenems Phase 2/Phase 3
Completed NCT03255759 - Actionable Results: Bloodstream Infection Molecular Assay Evaluation N/A
Active, not recruiting NCT03744728 - Genotypic Versus Phenotypic Susceptibility Testing of Positive Blood Cultures N/A
Terminated NCT00680459 - Ethanol Locks for the Treatment of Central Venous Line Infections Phase 3
Recruiting NCT04839653 - Efficacy and Safety of Selective Digestive Decontamination in the ICU With High Rates of Antibiotic-resistant Bacteria N/A
Recruiting NCT03896893 - Neonatal Bacterial Colonization Study N/A
Completed NCT05277350 - A Study Investigating the Safety, Recovery, and Pharmacodynamics of Multiple Oral Administrations of SNIPR001 in Healthy Subjects Phase 1
Recruiting NCT00843804 - Surveillance for Nosocomial Infections in Pediatric Cancer Patients N/A
Completed NCT00467272 - Catheter Related - Gram Positive Bloodstream Infections Phase 2
Recruiting NCT04658017 - GARNETâ„¢ Filter (GARNET Device) IDE Used in Chronic Hemodialysis Patients With a Bloodstream Infection N/A
Completed NCT04710212 - Screening for Colonization With Resistant Enterobacterales in Neutropenic Patients With Hematologic Malignancies
Not yet recruiting NCT06271031 - Process Mapping and Data Collection to Inform a Computer Simulation Model of Hospitalised Patients With Bloodstream Infection, Sepsis and Systemic Infection
Not yet recruiting NCT03991793 - Granzyme A in Patients With E. Coli Bacteremic Urinary Tract Infections